
    
      OBJECTIVES:

      Primary:

      To compare the pharmacokinetic characteristics of a single dose between CDP1 and the original
      drug Erbitux in healthy volunteers.

      Secondary :

      To compare the safety and immunogenic characteristics of the single dose between CDP1 and the
      original drug Erbitux in healthy volunteers.
    
  